PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
PaxMedica unveiled a Fireside Chat video featuring Howard Weisman, Chairman and CEO, providing a detailed company update with insights into recent achievements and advancements.
PaxMedica Announces Closing of $7.0 Million Public Offering
Closing previously announced public offering.
PaxMedica Announces Pricing of $7.0 Million Public Offering
Proceeds to Be Used to Advance Company's Development Programs
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
Key Updates and Achievements
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder.
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
Marks Important Step Prior to Filing NDA for African Sleeping Sickness
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
• Key Guidance Regarding NDA Filing Obtained
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)
IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023
PaxMedica announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023.
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference.
PaxMedica Appoints David Hough M.D. as Chief Medical Officer
Announces Additional Management Changes; Independent Directors Now Majority of Board
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update
PaxMedica provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023.
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results - These results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African Sleeping Sickness
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
VoxNova is the first purpose-built limited distribution specialty pharmacy benefit manager that is focused on ASD. The Company’s mission is to provide compassionate care and critical oversight using groundbreaking therapies for the treatment of people living with ASD. Under the agreement, VoxNova will have exclusive access to PaxMedica’s PAX-101 intravenous suramin in the United States for a period of up to seven years.
PaxMedica Comments on Common Stock Volatility
The management and Board of Directors of PaxMedica are aware of the recent market volatility in the company’s common stock. PaxMedica is not aware of any news that might be relevant to the recent share price fluctuations, however management takes its fiduciary responsibility very seriously, and have engaged the services of Shareholder Intelligence Services LLC (“ShareIntel”) to better understand the investor base and the trading behavior around the company’s securities.
PaxMedica CEO Interviewed by The BRAIN Foundation
CEO, Howard Weisman, participated in a webcast on Saturday, June 17th, hosted by The BRAIN Foundation. The core content of the webcast was an interview with Mr. Weisman by The BRAIN Foundation’s co-founder, Sarika Agrawal.
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder
PaxMedica has submitted a request to the South African Health Products Regulatory Authority (SAHPRA), seeking approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101. This trial will seek to enroll a total of 30 subjects with confirmed ASD, ages 4 to 18, at multiple sites in South Africa. This is the first new clinical trial on the safety, tolerability, and efficacy of suramin since the Company announced the results of its prior Phase II trial in 2021. Enrollment is expected to begin in Q4 2023, following SAHPRA’s potential approval later this summer.
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
PaxMedica has entered into an agreement with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder.
PaxMedica Completes HAT-301 Registrational Trial for PAX-101
The eligibility review and final enrollment for the company’s Real World Evidence study (HAT-301) has been completed. Patient eligibility was assessed for inclusion by an Independent Study Adjudication Committee which included a total of three subject matter expert medical reviewers.
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
PaxMedica provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023.
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
PaxMedica announced that Chief Executive Officer Howard Weisman will ring the Nasdaq Stock Market closing bell on Wednesday April 19, 2023. This comes to celebrate PaxMedica’s listing of its common shares on the Nasdaq Capital Market in August 2022 and April’s Autism Awareness Month.
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results
PaxMedica provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.
PaxMedica Holds Meeting of Scientific Advisory Board
PaxMedica announced that it held a Scientific Advisory Board meeting on March 10-12, 2023. A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States.
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
PaxMedica, Inc. has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together “Lind”).
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
PaxMedica today announced that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26 th .
PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
PaxMedica announced that the Company has launched a newly updated corporate website at www.paxmedica.com .
PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
PaxMedica announced it will be presenting at the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022 at the New York Athletic Club in New York City.
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
PaxMedica announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for up to $20 million with Lincoln Park Capital Fund, LLC ("Lincoln Park").
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results
PaxMedica provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022.
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
PaxMedica announced that it has initiated a Phase 3 trial, HAT-301, as part of its strategic plan to obtain US market approval of PAX-101 (intravenous suramin).
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
PaxMedica announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer. In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica’s pipeline products. The initial program underway is targeting antipurinergic drug therapies.